FDA warns about com­pound­ed semaglu­tide-based drugs

The FDA has warned the pub­lic that com­pound­ed ver­sions of pop­u­lar GLP-1 drugs Ozem­pic and We­govy may not in­clude the same in­gre­di­ents as the pre­scrip­tion med­ica­tions, and that has raised ques­tions about their safe­ty and ef­fec­tive­ness.

The reg­u­la­tor said Tues­day it has re­ceived re­ports of ad­verse events re­lat­ed to com­pound­ed ver­sions of semaglu­tide, the ac­tive in­gre­di­ent in Ozem­pic and We­govy. Some prod­ucts be­ing mar­ket­ed as semaglu­tide con­tain the salt for­ma­tion of semaglu­tide, which is not con­sid­ered safe or ef­fec­tive.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER